You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

immune oncology

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

The Immune Landscape of Epithelial Ovarian Cancer

Recruiting
  • Epithelial Ovarian Cancer
  • Collection of tumor samples, blood and vaginal and rectal swabs
  • Bellinzona, Switzerland
    Oncology Institute of Southern Switzerland
Aug 2, 2023

Inflammatory Arthritis, Immune-related Adverse Event Trial (Adalimumab, Prednisone)

Not yet recruiting
  • Inflammatory Arthritis
  • Immune-related Adverse Event
  • (no location specified)
Sep 13, 2023

Lung Cancer Stage IV Trial in Maastricht (Radiation)

Not yet recruiting
  • Lung Cancer Stage IV
  • Radiation
  • Maastricht, Netherlands
    Maastricht Radiation Oncology (Maastro)
Aug 29, 2023

Colitis Trial in Aalborg, Odense, London (Infliximab, Methylprednisolone, Prednisolone)

Not yet recruiting
  • Colitis
  • Aalborg, Denmark
  • +2 more
Jul 7, 2023

Education, Oncology, Immune Trial in Taipei (Immunotherapy Special Training Course (ISTC), Advanced Oncology Nurse Training

Recruiting
  • Education
  • +2 more
  • Immunotherapy Special Training Course (ISTC)
  • Advanced Oncology Nurse Training Course (AONTC)
  • Taipei, Taiwan
    National Taiwan University
Feb 20, 2023

NSCLC Trial in Rotterdam (Nutritional intervention, Immunotherapy)

Recruiting
  • Non-small Cell Lung Cancer
  • Rotterdam, Netherlands
    Erasmus MC
Jun 5, 2023

Breast Cancer, Hormone Receptor-positive Breast Cancer, Hormone Therapy Trial in Taipei City, Taipei (Palbociclib, Ribociclib,

Recruiting
  • Breast Cancer
  • +2 more
  • Taipei City, Taiwan
  • +1 more
Mar 15, 2023

Oncology Patients to Novel Coronavirus Vaccines (IROC)

Recruiting
  • Cancer
  • COVID-19 Vaccination
  • Carmel, Indiana
  • +1 more
Aug 2, 2022

Breast Cancer, Hematologic Malignancy, Immune Checkpoint Inhibitor-Related Myocarditis Trial in Weston (anonymized data

Recruiting
  • Breast Cancer
  • +4 more
  • anonymized data collection during programmed surveillance clinical follow up
  • Weston, Florida
    Cleveland Clinic Florida
Oct 27, 2022

Metastatic Melanoma, Immune Checkpoints Inhibitors, Gastrointestinal Microbiome (Bacterial and Viral) Trial in Ljubljana (Immune

Recruiting
  • Metastatic Melanoma
  • +3 more
  • Immune checkpoint inhibitor
  • Ljubljana, Slovenia
    Institute of Oncology Ljubljana
May 17, 2023

Immune Thrombocytopenia, Autoimmune Hemolytic Anemia, Evans Syndrome Trial in Graz (potential biomarkers)

Recruiting
  • Immune Thrombocytopenia
  • +3 more
  • potential biomarkers
  • Graz, Styria, Austria
    Pediatric Hematology-Oncology Outpatient Clinic
Sep 8, 2022

Axitinib Dose Reduction and Interruption for Adverse Event

Completed
  • Renal Cell Carcinoma
  • New York, New York
    Pfizer
Sep 15, 2022

Liquid Biopsy to Enable Diagnostics and Monitoring for

Recruiting
  • Lymphoproliferative Disorders
  • Lymphoproliferative Disorder Following Transplantation
  • Liquid biopsy
  • Basel, Switzerland
  • +5 more
Mar 24, 2023

Advanced Solid Tumor, Stereotactic Body Radiotherapy, Immune Checkpoint Inhibitor Trial in Peking (Cadonilimab, Stereotactic

Not yet recruiting
  • Advanced Solid Tumor
  • +4 more
  • Peking, Beijing, China
    Department of radiation oncology, Peking University Third Hospit
Jun 20, 2023

Oncology Trial in Berlin (moderate Whole Body Hyperthermia (mWBH))

Recruiting
  • Oncology
  • moderate Whole Body Hyperthermia (mWBH)
  • Berlin, Germany
    Klinik für Radioonkologie und Strahlentherapie
Apr 6, 2023

Malignancy, Immune System Diseases, Autoimmune Diseases Trial in Chapel Hill (Biospecimen Collection, Medical Chart Review,

Recruiting
  • Malignancy
  • +2 more
  • Biospecimen Collection
  • +2 more
  • Chapel Hill, North Carolina
    Lineberger Comprehensive Cancer Center at University of North Ca
Feb 11, 2022

HCC Trial in Hong Kong (Zabadinostat (CXD101) and Geptanolimab, Lenvatinib and Sorafenib)

Not yet recruiting
  • HCC
  • Zabadinostat (CXD101) and Geptanolimab
  • Lenvatinib and Sorafenib
  • Hong Kong, Hong Kong
    Department of Clinical Oncology, Prince of Wales Hospital
May 15, 2023

Immune Biomarker Study for Head and Neck Cancer

Recruiting
  • Head and Neck Cancer
  • +4 more
  • Sampling
  • Erlangen, Bavaria, Germany
  • +2 more
Jan 23, 2023

Hepatocellular Carcinoma Trial in Hong Kong (Durvalumab, Tremelimumab, Yttrium-90 radioembolisation)

Recruiting
  • Hepatocellular Carcinoma
  • Hong Kong, Hong Kong
    Department of Clinical Oncology, Queen Mary Hospital
Apr 10, 2023

Lung Cancer, Chronic Stress Disorder, Immune Checkpoint Inhibitors Trial in Changsha (Gut microbiota detection, Peripheral

Recruiting
  • Lung Cancer
  • +2 more
  • Gut microbiota detection
  • Peripheral immune cells signature detaction
  • Changsha, Hunan, China
    Department of Oncology, The Second Xiangya Hospital, Central Sou
Jul 26, 2022

Understanding immunE-related toXicities by multifACeT Profiling

Recruiting
  • Oncology
    • Chelsea, London, United Kingdom
      Royal Marsden NHS Foundation Trust
    Apr 21, 2022

    Metastatic or Locally Advanced Unresectable Solid Tumors Trial in Canada, Spain, United States (M1774, Drug A (DNA Damage

    Recruiting
    • Metastatic or Locally Advanced Unresectable Solid Tumors
    • Houston, Texas
    • +4 more
    Jul 7, 2022

    Melanoma Trial in Boulogne-Billancourt (venous puncture, tumoral biopsy)

    Recruiting
    • Melanoma
    • venous puncture
    • tumoral biopsy
    • Boulogne-Billancourt, France
      Dermato-oncology department, Ambroise Paré hospital, APHP
    Feb 9, 2022

    Non-cutaneous Squamous Cell Carcinoma of Head and Neck Trial in United States (ALKS 4230, Pembrolizumab)

    Completed
    • Non-cutaneous Squamous Cell Carcinoma of Head and Neck
    • Miami, Florida
    • +5 more
    Nov 10, 2022

    Small Cell Lung Cancer, Immunotherapy Trial in Changsha (chronic psychological stress)

    Recruiting
    • Small Cell Lung Cancer
    • Immunotherapy
    • chronic psychological stress
    • Changsha, Hunan, China
      Department of Oncology, The Second Xiangya Hospital, Central Sou
    Jul 22, 2023